Introduction {#sec1-1}
============

Osteosarcoma is the most common primary bone tumor in children and adolescents (Arndt et al., 2012). According to the statistics, osteosarcoma representing approximately 3.4% of all childhood cancers and 56% of malignant bone tumors in children (Geller et al., 2010). It was reported that osteosarcoma is the second most frequent cause of cancer-related death in adolescents (Liu et al., 2016; Sobhan et al., 2017). In humans, the peak incidence of osteosarcoma occurs in the second decade of life, during periods of rapid skeletal growth (Gorlick et al., 2003; Geller et al., 2010). Based on epidemiological studies, osteosarcoma predominantly occurred in the femur (42%, with 75% of tumors in the distal femur), followed by the tibia (19%, with 80% of tumors in the proximal tibia), and the humerus (10%, with 90% of tumors in the proximal humerus) (Ottaviani et al., 2009).

Osteosarcoma is a complex, multistep, and multifactorial disease (Sobhan et al., 2017). The molecular mechanism involved in the tumorigenesis of osteosarcoma is not well understood yet (Li et al., 2016). Many environmental factors (such as radiation and chemicals exposure) and genetic (family history and several putative single genes) are known to contribute to the development of osteosarcoma (Ottaviani et al., 2009; Tang et al., 2016; Sobhan et al., 2017).

To date, several studies identified different putative genetic susceptibility polymorphisms for risk of osteosarcoma development, which participates in several critical cellular functions such as repair of damaged DNA; however, the statistical power of these studies was limited by small sample sizes. Recently, a few studies have investigated the genetic link between the important DNA repair genes variants, including ERCC2, NBN, and RAD51 and increased risk of developing osteosarcoma. However, the results have been inconsistent. In addition, the data regarding the role of those genetic polymorphisms in osteosarcoma risk are sparse. It is clear that meta-analysis can be used to increase power and answer questions not posed by the individual studies. Therefore, the objective of this systematic review and meta-analysis was to detect the potential association between osteosarcoma susceptibility and ERCC2 rs13181 and rs1799793, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321, and rs12593359 polymorphisms.

Materials and Methods {#sec1-2}
=====================

Search Strategy {#sec2-1}
---------------

We searched PubMed, Google Scholar, and ISI web of knowledge electronic databases to identify eligible studies that were published before February 2017. The used search terms were: "DNA repair gene" and "ERCC2", "NBN, "RAD51" and "bone tumors", "bone malignancy", "osteosarcomas", and "polymorphism", "polymorphisms", "variant", or "mutation". In addition, we checked references of all those retrieved articles to identify more relevant papers.

Selection Criteria {#sec2-2}
------------------

We used the following inclusion criteria to identify articles for our meta-analysis: (1) the studies assessed the association between the ERCC2, NBN, RAD51 polymorphisms, and osteosarcoma risk; (2) studies with a case-control or cohort design; and (3) studies provided sufficient published data to estimate an odds ratio (OR) with a 95% confidence interval (95% CI). In case of more than one eligible article with overlapping data by the same authors, we included the most recent or the largest one.

Data Extraction {#sec2-3}
---------------

In the current meta-analysis, two authors independently searched and identified the eligible articles based on the inclusion criteria. The following information were extracted from each study: first author, year of publication, country (ethnicity), number of cases and controls, and the genotype frequencies of the cases and controls.

Statistical Analysis {#sec2-4}
--------------------

The statistical analysis for the current meta-analysis study was performed using the comprehensive meta-analysis (CMA) V2 software (Biostat, USA). In the current meta-analysis, all P values were considered two-sided, and P = 0.05 was set as the threshold value for statistical significance. To evaluate the associations between ERCC2 rs13181 polymorphism and osteosarcoma risk, the pooled odds ratio (OR) and associated 95% confidence interval (CI) were calculated under five genetic contrasts, including allelic (G vs. T), heterozygote (GT vs. TT), homozygote (GG vs. TT), dominant (GG+GT vs. TT), and recessive (GG vs. GT+TT). In addition, due to insufficient data, we used only the dominant genetic contrast to calculate ORs for ERCC2 rs1799793 (GA+AA vs. GG), NBN rs709816 (TT+TC vs. CC) and rs1805794 (CC+CG vs. GG), RAD51 rs1801320 (CC+CG vs. GG), rs1801321 (TT+GT vs. GG), and rs12593359 (GG+GT vs. TT) polymorphisms. The I2 statistics was also employed to assess the risks of heterogeneity. Therefore, in the current meta-analysis the I2 values of 25, 50, and 75% meant a low, moderate, and high heterogeneity, respectively, (Higgins et al., 2003; Khoram-Abadi et al., 2016). Moreover, a random effects model using the DerSimonian was utilized to calculate the OR and 95% CI for comparisons with moderate to high heterogeneity (P-value \> 0.1 and I^2^ \> 25%) (DerSimonian et al., 1986). If the Q test and the I2 statistics (P-value \< 0.1 and I^2^ \< 25%) both indicated no existence of heterogeneity, a fixed model with the Mantel-Haenszel method would be employed to pool data. We removed each study in turn for sensitivity analyses, and the remaining studies were reanalyzed to assess the stability of the meta-analysis results. Funnel plots and Egger's test were used to examine publication bias (P\<0.05) (Egger et al., 1997). Chi-Square test was used to determine the frequency distribution of genotypes, which were met the Hardy--Weinberg equilibrium (HWE).

Results {#sec1-3}
=======

Characteristics of the Pooled Case-Control Ctudies {#sec2-5}
--------------------------------------------------

Through electronic search and considering the inclusion criteria, a total of seven relevant studies concerning ERCC2, NBN, and RAD51 gene polymorphisms and osteosarcoma were initially identified. However, three studies were excluded because they were about DNA repair genes association with osteosarcoma treatment. The final pool of eligible studies included four articles (Goričar et al., 2015; Jin et al., 2015; Ma et al., 2015; Wang et al., 2016) with 540 cases, and 1228 controls for ERCC2, NBN, and RAD51 gene polymorphisms in a sample of Slovenian population (Goricar et al. 2015) and three in Chinese population (Jin et al. 2015; Ma et al. 2015; Wang et al. 2016). All studies were case--control in design. In searching reference lists, relevant meta-analyses and reviews, we did not find additional papers. General characteristics of the included studies are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of Studies Included in the Meta-Analysis of ERCC2, NBN, and RAD51 Gene Polymorphisms and Osteosarcoma.

  First author          Country (Ethnicity)    Case/Control              Cases                     Controls                    HWE
  --------------------- ---------------------- -------------- ----- ---- ------- ----- ----- ----- ---------- ---- ----- ----- ---------
  ERCC2 rs13181                                               TT    TG   GG      T     G     TT    TG         GG   T     G     
  Jin et al. 2015       China (Asian)          148/298        86    62                       181   117                         
  Ma et al. 2015        China (Asian)          141/282        96    32   13      224   58    206   58         18   470   94    \<0.001
  Wang et al. 2016      China (Asian)          172/275        90    66   16      246   98    155   103        18   413   139   0.873
  ERCC2 rs1799793                                             AA    AG   GG                  AA    AG         GG   A     G     
  Jin et al. 2015       China (Asian)          148/298        84    64                       201   97                          
  Ma et al. 2015        China (Asian)          141/282        60    62   19      182   100   134   117        31   385   179   0.475
  NBN rs709816                                                CC    CT   TT                  CC    CT         TT               
  Goricar et al. 2015   Slovenia (Caucasian)   79/373         29    50                       139   234                         
  Jin et al. 2015       China (Asian)          148/298        55    93                       115   183                         
  NBN rs1805794                                               GG    GC   CC                  GG    GC         CC               
  Goricar et al. 2015   Slovenia (Caucasian)   79/373         11    68                       33    340                         
  Jin et al. 2015       China (Asian)          148/298        52    96                       127   171                         
  RAD51 rs1801320                                             GG    GC   CC                  GG    GC         CC               
  Goricar et al. 2015   Slovenia (Caucasian)   78/373         69    9                        304   69                          
  Jin et al. 2015       China (Asian)          148/298        101   47                       213   85                          
  RAD51 rs1801321                                             GG    GT   TT                  GG    GT         TT               
  Goricar et al. 2015   Slovenia (Caucasian)   79/373         25    54                       133   240                         
  Jin et al. 2015       China (Asian)          148/298        88    60                       187   111                         
  RAD51 rs12593359                                            TT    TG   GG                  TT    TG         GG               
  Goricar et al. 2015   Slovenia (Caucasian)   79/373         22    57                       103   270                         
  Jin et al. 2015       China (Asian)          148/298        49    99                       105   193                         

Meta-Analysis Results {#sec2-6}
---------------------

[Table 2](#T2){ref-type="table"} lists the main results of the meta-analysis for ERCC2, NBN, and RAD51 polymorphisms. For ERCC2 rs13181 polymorphism, no significant association was found between this polymorphism and osteosarcoma when all eligible studies were pooled into meta-analysis in any genetic contrast (G vs. T: OR= 1.224, 95% CI: 0.970-1.545, p= 0.088; GT vs. TT: OR= 1.135, 95% CI: 0.830-1.552, p= 0.428; GG vs. TT: OR= 1.247, 95% CI: 0.738-2.108, p= 0.409; GG+GT vs. TT: OR= 1.174, 95% CI: 0.929-1.484, p= 0.179; GG vs. GT+TT: OR= 1.476, 95% CI: 0.886-2.460, p= 0.135).

###### 

Results of Meta-Analysis for ERCC2, NBN, and RAD51 Gene Polymorphisms and Osteosarcoma

  Polymorphism       Genetic Model   Type of Model   Heterogeneity           Odds ratio                  
  ------------------ --------------- --------------- --------------- ------- ------------- ------------- -------
  ERCC2 rs13181                                                                                          
  G vs. T            Fixed           0               0.696           1.224   0.970-1.545   0.088         
  GT vs. TT          Fixed           0               0.829           1.135   0.830-1.552   0.428         
  GG vs. TT          Fixed           0               0.432           1.247   0.738-2.108   0.409         
  GG+GT vs. TT       Fixed           0               0.909           1.174   0.929-1.484   0.179         
  GG vs. GT+TT       Fixed           0               0.974           1.476   0.886-2.460   0.135         
  ERCC2 rs1799793    Dominant        Fixed           70.49           0.066   1.279         0.912-1.793   0.154
  NBN rs709816       Dominant        Fixed           0               0.911   1.047         0.763-1.437   0.775
  NBN rs1805794      Dominant        Fixed           73.32           0.053   1.126         0.789-1.608   0.513
  RAD51 rs1801320    Dominant        Fixed           61.85           0.105   0.977         0.675-1.416   0.904
  RAD51 rs1801321    Dominant        Fixed           0               0.902   1.167         0.848-1.604   0.343
  RAD51 rs12593359   Dominant        Fixed           0               0.761   1.057         0.759-1.470   0.744

In the current meta-analysis only the dominant genetic contrast was determined for ERCC2 rs1799793, NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321, and rs12593359 polymorphisms, due to insufficient data. However, we did not find a significant association between the ERCC2 rs1799793 (GA+AA vs. GG: OR= 1.279, 95% CI: 0.912-1.793, p= 0.154), NBN rs709816 (OR= 1.047, 95% CI: 0.763-1.437, p= 0.775), NBN rs1805794 (OR= 1.126, 95% CI: 0.789-1.608, p= 0.513), RAD51 rs1801320 (OR= 0.977, 95% CI: 0.675-1.416, p= 0.904), RAD51 rs1801321 (TT+GT vs. GG: OR= 1.167, 95% CI: 0.848-1.604, p= 0.343), RAD51 rs12593359 (GG+GT vs. TT: OR= 0.761, 95% CI: 0.759-1.470, p= 0.744) polymorphisms and osteosarcomas.

Heterogeneity Test {#sec2-7}
------------------

We used Q-test and I^2^ statistics to test the heterogeneity among the studies. No heterogeneity was observed in either polymorphisms (A vs. G) as well as the dominant genotype contrast for overall cancer, which was included for the analysis (Overall allele, A vs. G: Q=31.08, P~heterogeneity~ = 0.186, I^2^= 19.58; Overall dominant contrast, AA+GG vs. GG: Q= 25.76, P~heterogeneity~ = 0.11, I^2^ = 25.76).

Publication Bias {#sec2-8}
----------------

Funnel plot and Egger's linear regression were performed to assess the publication bias of the included studies. The shapes of the funnel plots did not reveal any evidence of obvious asymmetry ([Figure 2](#F1 F2){ref-type="fig"}). The results of Egger's test also showed no strong statistical evidence of publication bias (P~Beggs~ = 1.000, P~Eggers~= 0.417, [Figure 2](#F2){ref-type="fig"}).
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![Begg's Funnel Plots of the ERCC2 rs13181 Polymorphism and Osteosarcoma Risk for Publication Bias Test in Dominant Genetic Contrast (GG+GT vs. TT). Each point represents a separate study for the indicated association.](APJCP-18-1315-g002){#F2}

Discussion {#sec1-4}
==========

ERCC2, NBN, and RAD51 genes play an important role in DNA repair pathways (Damaraju et al., 2006). Several important single nucleotide polymorphisms (SNPs) have been identified in the loci. Recently, several case control epidemiological studies have evaluated the association between RAD51, ERCC2 and NBN polymorphisms and risk of a large range of cancers (Ji et al., 2015).

The Human RAD51 gene, one of the key proteins for homologous recombination (HR), plays a crucial role in maintaining the genetic stability of the cell through HR repair of DNA double-strand breaks (DSBs) (Richardson, 2005). It is well known that RAD51 is the major component of the HR pathway in combination of BRCA1 and BRCA2 (Roy et al., 2011). However, the nature of interaction between BRCA1 and RAD51 is still unknown. It is postulated that the association is likely to be indirect and possibly mediated by BRCA2 (O'Donovan et al., 2010). RAD51 is involved in the search for homology and strand pairing stages of the process. RAD51 overcomes internal DNA bonding forces to unwind and separate DNA strands and also to compete with other DNA binding proteins (Thacker, 2005). The human RAD51 gene is found to be located on chromosome 15q15.1, span \>39 kb, contains 10 exons and encodes a 339 amino acid protein (Chen et al., 2016). RAD51 gene belongs to a region which exhibits a high loss of heterozygosity (LOH) in a large range of malignancies such lung, the colorectum, and the breast (Lose et al., 2006).

The excision repair cross-complementing rodent repair deficiency, group 2 (ERCC2) or XPD (Xeroderma Pigmentosum Complementary group D) plays an important role in transcription-coupled nucleotide excision repair (NER) pathway (Vashisht et al., 2015). ERCC2 is a 5'-3' ATP-dependent helicase as a subunit of the basal transcription factor TFIIH (Fukuda et al., 2001; Compe et al., 2012). Human XRCC1 gene maps to chromosome 19q13.32 and is composed of 23 exons. It spans approximately 54336 bp and encodes a protein of 760 amino acids with a molecular weight of 86,900 (Li et al., 2013; Forat-Yazdi et al., 2015). Several validated single nucleotide polymorphisms (SNPs) in ERCC2 are listed in the dbSNP database, which play a causative role in DNA repair-deficiency diseases, including Xeroderma Pigmentosum (XP), Trichothiodystrophy (TTD), and Cockayne Syndrome (CS) (Lehmann 2003). These diseases characterized by high ultraviolet-light hypersensitivity, a high mutation frequency, and cancer-proneness, as well as some mental and growth retardation and probably aging (Benhamou ET AL., 2005). Additionally, it is reported that different mutations in the ERCC2 (XPD) gene may lead to one of 6 different clinical disorders: XP, XP neurological disease, TTD, the XP/CS complex, XP/TTD complex or a severe form of CS known as COFS (cerebral, ocular, facial, skeletal syndrome) (Kraemer et al., 2007).

The NBN gene encoding a tumor suppressor protein belongs to the DNA DSBs repair genes and encodes a protein called nibrin (also known NBS1, p95 or NBN), which participates in several critical cellular functions, including the repair of damaged DNA (Czornak et al., 2008; Berardinelli et al., 2013). The gene is located on chromosome 8 at 8q21and consists of 16 exons, which spans a region of more than 50 kb. Its product nibrin is a 95-kDa protein, which forms a multiprotein complex with hMRE11 and hRAD50 (MRN) (OMIM; Uzunoglu et al., 2016). Mutations in the NBN gene lead to an autosomal recessive disorder named Nijemen breakage syndrome (NBS), a radiation-sensitivity disorder with multiple deficiencies, which may result in susceptibility to cancers such as breast cancer (Schröder-Heurich et al., 2014; Uzunoglu et al., 2016).

Considering the functional significance of ERCC2, NBN, and RAD51 genes in carcinogenesis, it is speculated that ERCC2, RAD51, and NBN polymorphisms may be a potential susceptibility factor for osteosarcoma. However, a few studies evaluated the association between ERCC2, NBN, and RAD51 polymorphisms and osteosarcoma risk (Goričar et al., 2015; Jin et al., 2015; Ma et al., 2015; Wang et al., 2016). To the best of our knowledge, this meta-analysis represents the first one investigating the association between ERCC2 (rs13181 and rs1799793), NBN (rs709816 and rs1805794), RAD51 (rs1801320, rs1801321, and rs12593359) polymorphisms and osteosarcoma risk. Notwithstanding, our results suggested that ERCC2 (rs13181 and rs1799793), NBN (rs709816 and rs1805794), RAD51 (rs1801320, rs1801321, and rs12593359) polymorphisms might not be associated with osteosarcoma risk. The finding was consistent with the individual study by Jin et al., reported the association of ERCC2 rs1799793 and NBN rs1805794 polymorphisms with risk of osteosarcoma (2015). Additionally, they held that these two polymorphisms are associated with an increased risk of osteosarcoma in females (Jin et al., 2015). However, the other included study, with 79 osteosarcoma cases and 373 controls from Slovenia, by Goricar et al. found no association between NBN rs709816 and rs1805794, RAD51 rs1801320, rs1801321, and rs12593359 polymorphisms and risk of osteosarcoma (2015). However, they demonstrated that the NBN rs1805794 polymorphism is significantly associated with risk of osteosarcoma in younger patients (\<30 years) (Goričar et al., 2015; Jin et al., 2015). Therefore, these two individual studies indicated the age-and gender-specific effects of ERCC2 rs1799793 polymorphism and in particular NBN rs1805794 polymorphism on risk of the osteosarcoma development.

Although we conducted the first meta-analysis investigating the association between ERCC2, NBN and RAD51 genes polymorphism and risk of osteosarcoma, there were some limitations. First, the present meta-analysis involved only four studies, the meta-analysis was relatively small in comparison with other meta-analyses; therefore, we cannot generalize our findings. To validate the present meta-analysis results, more comprehensive studies with larger sample size must be included in future investigations. Second, we only included published articles and also searched literature written in English; hence, the existence of high risk of potential bias must be considered. Finally, the current meta-analysis was based on unadjusted ORs estimates, the eligible studies did not describe the age and gender distribution between cases and controls. Therefore, further evaluation of adjustments of risk factors such as age, gender and the potential interactions among gene--gene and gene--environment was not possible for us.

In summary, the current meta-analysis findings indicated no significant association between ERCC2 (rs13181 and rs1799793), NBN (rs709816 and rs1805794), RAD51 (rs1801320, rs1801321, and rs12593359) polymorphisms and osteosarcoma risk. Due to small sample size, this conclusion should be interpreted with caution. Further well-designed and large-scale studies are recommended considering gene--gene and gene--environment interactions for investigation of such associations.
